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Abstract
Therapeutic resistance remains the most challenging aspect of treating cancer. Raf kinase inhibitory protein (RKIP) emerged
as a molecule capable of sensitizing cancerous cells to radio- and chemotherapy. Moreover, this small evolutionary
conserved molecule, endows significant resistance to cancer therapy when its expression is reduced or lost. RKIP has been
shown to inhibit the Raf-MEK-ERK, NFkB, GRK and activate the GSK3b signaling pathways. Inhibition of Raf-MEK-ERK and
NFkB remains the most prominent pathways implicated in the sensitization of cells to therapeutic drugs. Our purpose was
to identify a possible link between RKIP-KEAP 1-NRF2 and drug resistance. To that end, RKIP-KEAP 1 association was tested
in human colorectal cancer tissues using immunohistochemistry. RKIP miRNA silencing and its inducible overexpression
were employed in HEK-293 immortalized cells, HT29 and HCT116 colon cancer cell lines to further investigate our aim. We
show that RKIP enhanced Kelch-like ECH-associated protein1 (KEAP 1) stability in colorectal cancer tissues and HT29 CRC cell
line. RKIP silencing in immortalized HEK-293 cells (termed HEK-499) correlated significantly with KEAP 1 protein degradation
and subsequent NRF2 addiction in these cells. Moreover, RKIP depletion in HEK-499, compared to control cells, bestowed
resistance to supra physiological levels of H2O2 and Cisplatin possibly by upregulating NF-E2-related nuclear factor 2 (NRF2)
responsive genes. Similarly, we observed a direct correlation between the extent of apoptosis, after treatment with
Adriamycin, and the expression levels of RKIP/KEAP 1 in HT29 but not in HCT116 CRC cells. Our data illuminate, for the first
time, the NRF2-KEAP 1 pathway as a possible target for personalized therapeutic intervention in RKIP depleted cancers.
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Introduction
RKIP is a small evolutionary conserved protein that was first
identified as a physiological inhibitor of the Raf-MEK-ERK pathway
[1]. RKIP is well known for its metastasis suppression function in
various cancer types. Loss or diminution of RKIP expression has been
associated with increasing number of aggressive cancers
[2,3,4,5,6,7,8]. Moreover, recent data implicated RKIP depletion in
radio- and chemotherapeutic resistance both in vitro [9,10,11,12,13]
and in vivo [14,15]. The mechanisms behind such resistance remain
elusive. Although current data implicate NF-kB activation by RKIP
diminution as the most likely mechanism behind apoptotic cell death
resistance. RKIP has been shown to negatively interfere with NF-kB
signaling, by binding to NIK, TAK1, and TRAF6 [16,17,18].
Recently, elegant experiments illuminated the NF-kB-Snail-RKIP
circuitry as possible mechanism for chemotherapeutic resistance in
cancer cells [11] and that RKIP expression reversed cancer cells
resistance to drugs and TRAIL induced apoptosis [10]. RKIP
expression may be induced by chemotherapeutic drugs and this
correlated with the onset of apoptosis [12]. Moreover, downregulation
of RKIP by siRNA has been shown to confer resistance to anticancer
drugs in inherently sensitive cancer cells [12].
Previously, we have reported that RKIP depletion in HEK-293
cells induced an intense reactive oxidative stress response that
culminated in the activation of p38 and degradation of GSK3b
protein [19]. It is well established that oxidative stress induces
NRF2 activation through the uniquitination of KEAP 1 protein,
which binds and inhibits NRF2 nuclear translocation [20,21].
NRF2 is a transcription factor originally identified as a significant
upregulator of intracellular antioxidants and phase II detoxifica-
tion proteins containing ARE-cis acting element [22]. Later,
growth, redox-regulating genes, ubiquitin-mediated proteosomal
degradation and redox-related genes were identified as targets for
NRF2 regulation [23,24]. Therefore, NRF2 activation appears to
confer cell survival benefit under detrimental environmental
conditions. In cancer, NRF2 has been shown to be upregulated
in more than 90% of head and neck squamous cancers [25] and
was shown to determine chemoresistance in type II endometrial
cancer [26]. Moreover, KEAP 1 was shown to be frequently
inactivated by mutation or loss of heterozygosity in lung cancer
[27,28]. Given the intense induction of reactive oxygen species
(ROS) in RKIP depleted HEK-499 cells, testing a hypothesis that
links RKIP depletion or loss in cancers and immortalized cells with
KEAP 1 destabilization and consequently NRF2 activation
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29532appears very attractive. Here, we report, for the first time, that
KEAP1 protein expression in colorectal cancer is associated with
RKIP stability and that the KEAP 1-NRF2 pathway may be a
novel target in RKIP induced drug resistance.
Results and Discussion
RKIP-level modulation influences KEAP 1 protein in-vitro
KEAP 1 is a substrate adapter of a Cullin 3-based E3 ubiquitin
ligase complex that binds NRF2 and degrades it in stress-free
conditions through the proteosome pathway [29]. KEAP1 is the
major sensor for ROS in cells. Upon exposure to oxidative stress,
Cys 272 and Cys 288 get modified and Cys 226 and Cys 613 are
induced to form intramolecular disulfide bond and another
intermolecular disulfide bond at Cys 151 linking two KEAP 1
molecules together that culminates in the inactivation of KEAP1
and stabilization of NRF2 [30,31,32].
To elaborate on the relationship between RKIP and KEAP 1
proteins, we stably modulated RKIP level in vitro. The HEK-499
cells, derived directly from HEK-293 cells by miRNA silencing
RKIP, and the Flp-In T-Rex-293 cells with Doxycycline inducible
RKIP construct that elevate RKIP to slightly above physiological
level [19,33] were used in this study. We have chosen the HEK-
293 immortalized cells to further investigate the RKIP-KEAP 1-
NRF2-therapeutic resistance cascade because these cells have been
well characterized (genetically and biochemically) by us.
In RKIP silenced HEK-499 cells, KEAP 1 protein was
significantly underexpressed compared to HEK-293 control cells
(Figure 1A). Conversely, inducing RKIP in Flp-In T-Rex-293
cells, stabilized KEAP 1 protein compared to uninduced cells
(Figure 1B). Similarly, in HT29 colorectal cancer cells, the
overexpression of RKIP stabilized KEAP 1 protein level
(Figure 1C). However, this direct relationship between RKIP
and KEAP 1 protein levels was not observed in the HCT116 CRC
cell lines, that has codon-13 Ki-Ras oncogene mutation (data not
shown), indicating that the proposed RKIP-KEAP 1 relationship
may be a cell-specific phenomena. The basal-level changes in
KEAP 1 protein were not due to altered transcription of the KEAP
1 gene because silencing or induction of RKIP expression did not
significantly affect KEAP 1 mRNA levels in HEK-499 or HT29
cells respectively (Figure 1D and 1E). These data indicate that
RKIP modulation regulates KEAP 1 post-transcriptionally. To
explore this further, we subjected HEK-293 and their RKIP-
silenced derived cells (HEK-499) to protein synthesis inhibitor
Cycloheximide for up to 12 hours. In control HEK-293 cells, the
half-life of KEAP 1 protein was around 8 hours with significant
degradation observed after 12 hours of treatment (Figure 1F). In
RKIP depleted, HEK-499 cells, KEAP 1 half-life was less than
4 hours (Figure 1F). KEAP 1 protein degradation was even
documented after 2 hours of Cycloheximide treatment (Supple-
mentary Figure S1). These data strongly indicate that RKIP loss
causes a rapid reduction in the basal level of KEAP 1 protein by
accelerating its rate of degradation. Conversely, in HT29 cells,
overexpressing RKIP (fRKIP), the half-life of KEAP 1 protein was
significantly increased to around 19 hours compared to control
HT29 cells (Figure 1, panels G and H).
Antioxidant treatments rescue KEAP 1 protein expression
in RKIP-silenced HEK-499 cells
The regulation of KEAP 1 protein is poorly understood.
However, increased ROS are known to induce the ubiquitination
of KEAP1 [34,35]. We, therefore, examined ROS in HEK-499
and their equivalent control-HEK-293 cells using dihydro-
ethidium bromide (DHE), a well-known, indicator of cellular
ROS. Figure 2A shows a significant increase in ROS in HEK-499
cells when compared to corresponding control values. Consistent
with these data is our previous findings, documenting that RKIP
depletion induced H2O2 production in cells and the subsequent
induction of antioxidant enzymes [19,33,36]. To establish whether
RKIP reduces KEAP 1 by an oxidative stress mediated
mechanism, we administered N-acetylcysteine (N-Ac) and/or a-
Lipoic acid (ALA), two of the well-known antioxidants. [19]. As
shown in Figure 2A, pretreatment of HEK-499 cells with N-Ac
and/or ALA reduced the cellular levels of ROS as indicated by the
decrease in DHE red color formation, More interestingly, these
treatments in HEK-499 cells also significantly increased KEAP 1
protein content (Figure 2B and 2C) with subsequent reduction in
NRF2 level, a transcription factor that is normally targeted for
ubiquitination by KEAP 1 (Figure 2C). It is worthy of note that the
above treatment regimen did not alter RKIP protein level in
HEK-293 control cells (Figure 2B). Taken together, these data
advance the notion that antioxidant treatment has the potential of
rescuing KEAP 1 protein in RKIP depleted HEK-499 cells and
that ROS may, partly, be the connecting nexus between RKIP
and KEAP 1 in these cells. Although,, the increase in KEAP 1,
albeit significant did not elevate KEAP 1 protein to levels seen in
the original HEK-293 control cells, indicating that additional
mechanism(s) may also be responsible for the RKIP protection of
KEAP 1 from degradation. For example, RKIP may directly bind
KEAP 1 or modulates other factors that protect KEAP 1from
degradation. However, using protein-protein interaction micro-
array [19] and direct immunoprecipitation (Data not shown), we
were unable to demonstrate any binding affinity between RKIP
and KEAP 1 proteins. Recent data show that Sequestosome 1
(SQSTM1) is a binding partner of KEAP 1 and aids in its
degradation [36]. Our microarray data obtained from silencing
RKIP elucidated no relationship between RKIP modulation and
SQSTM1 at mRNA level [33]. Therefore, more targeted
experiments, using inducible RKIP promoter elements in a better
suited cell lines, are required to confirm or offer alternative
connections between RKIP-KEAP 1 proteins.
We next asked whether RKIP loss/reduction was also
associated with decreased KEAP 1 level in a disease based Model
in vivo. Accordingly, a colorectal cancer (CRC) was used as a
model for two reasons: firstly, RKIP loss/reduction seems to occur
in about 20% of this cancer [2] and secondly, KEAP1 expression
has not been previously evaluated in colorectal cancer.
Loss of RKIP expression correlates with diminution of
KEAP 1 protein level in vivo
To verify our in vitro finding, and elaborate on the relationship
between RKIP and KEAP 1 proteins, we studied the expression of
these proteins in 105 CRC tissues using immunohistochemistry.
We found that KEAP 1 expression was lost in 22 (21%) and
diminished/reduced in 23 (21.9%) of the CRC cases (Figure 3).
Moreover, our data elicited a significant association between the
expression levels of RKIP and KEAP 1 in CRC tissues with
Spearman’s correlation of 0.4260.09 S.E at p#0.0001 (Table 1).
KEAP 1 is frequently mutated in lung cancer and more so in
adenocarcinomas [27]. Moreover, loss of heterozygosity at
19p13.2, where KEAP 1 is localized, occurred in 41% of non-
small cell lung cancer cases [37]. Our data suggest that KEAP 1
protein loss or reduction is a significant event in colorectal cancer
and that it may be causally related, in part, to RKIP expression
loss or diminution in vivo. These data give credence to our in vitro
findings. However, given the small size of this cohort, our data
needs to be interpreted with caution and a larger cohort to further
elaborate on the KEAP 1 protein/gene status in CRC, correlate its
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to RKIP protein, is now warranted.
Loss of RKIP induces NRF2 nuclear accumulation
ROS has been well established as a major activator of NRF2
through shifting the ubiquitination pathway towards KEAP 1
protein [21,38]. We, therefore, examined NRF2 protein level in
HEK-499 cells using western blotting. Total NRF2 was elevated in
HEK-499 cells (Figure 4A), with concomitant increase of NRF2 in
the nuclear fraction of HEK-499 cells compared to their controls
(Figure 4B). This data was confirmed using confocal immunoflu-
orescence (Figure 4C). Conversely, in RKIP overexpressing cells,
NRF2 expression level was lower compared to uninduced cells
(Figure 4A and 4C). NRF2 is a well characterized molecule that is
known to enhance drug and therapeutic resistance through the
transcriptional upregulation of antioxidants and phase II detox-
ification genes containing Antioxidant Response Elements (ARE-
cis acting element) [22]. To further support our NRF2 data, we
tested the RNA expression of NQO1 [39], GST family [40], AKR
[41], MAF [42] and other molecules that have ARE cis-acting
element and are known to be transcriptionally induced by NRF2
[22,43]. Table 2 shows that genes related to phases I and II
oxidation, reduction, hydrolysis and conjugation enzymes known
to have chemopreventive properties, were upregulated at the
mRNA level in HEK-499 cells (Figures 5A and 5B). Nine of these
genes were also examined in doxycycline inducible cells overex-
pressing RKIP, normalized to uninduced cells and found to be
either unchanged or underexpressed (Figure 5C and 5D).
Quantitative RKIP mRNA and protein levels from the corre-
sponding cells are shown in figure 5, panels A, C and E
respectively.
Our data, therefore, suggest that RKIP repression induces
NRF2 nuclear accumulation and the transcriptional upregulation
of NRF2-dependant drug resistant genes, giving further credence
to our RKIP/KEAP 1-related findings. It is worthy of note that
other, non KEAP 1-related mechanisms, can also influence NRF2
levels. For example, activated GSK3b is known to phosphorylate
FYN, which accumulates in the nucleus and in turn phosphory-
lates NRF2 at Tyr-568 leading to its ubiquitination and
degradation [44]. Our previous work also supports this Redox-
divergent pathway as a plausible mechanism of NRF2 addiction
since GSK3b was previously found inactivated in HEK-499 cells
in response to RKIP silencing [19]. Our data illuminates NRF2
activation as a novel mechanism through which RKIP protein
reduction or loss probably bestows resistance to therapy. We next
tested this notion.
Loss of RKIP augments chemoresistance in HEK-499 and
HT29 cells
To examine if RKIP silencing may bestow survival advantage to
cells secondary to the overexpression of antioxidants and
chemoprotective genes, we subjected HEK-499 cells to increasing
concentrations of H2O2 or Cisplatin (Figure 6). Using an in vitro
WST ELISA assay, we documented a significant survival
advantage in HEK-499 cells (31.6% of surviving HEK-499 cells
versus 19.7% in control cells) at H2O2 concentrations of 50 mM
(Figure 6A). Conversely, the induction of RKIP by Doxycycline in
Flp-In T-Rex-293 cells induced substantial cellular death (Sup-
plementary Figure S2). This observation was not Doxycycline
dependent since increasing Doxycycline concentration did not
induce the expression of RKIP beyond 2.7 folds seen with 100 ng/
ml of doxycycline treatment compared to uninduced cells. Data
obtained from the Flp-In T-Rex-293 cells need to be interpreted
cautiously because Doxycycline treatment may itself influence
biochemical or other parameters that were not controlled for in
this study (i.e the use of Doxycycline only on wild-type cells or cells
without RKIP insert plasmids). Nevertheless, increasing Doxycy-
cline concentration by 5-foldes did not influence apoptosis beyond
what was expected from inducing RKIP by 2.7 folds (Supple-
mentary Figure S2) Our data are in line with previous work
showing that RKIP sensitizes cells to apoptosis [10,12] and that, as
anticipated, its loss or silencing bestows resistance to supra-
physiological levels of H2O2. Similarly, using MTT assay,
Figures 6B and 6C show that treating HEK-499 cells with
increasing Cisplatin concentrations induced significantly less
cytotoxicity in HEK-499 compared to control cells. We next
utilized Annexin V to detect the effects of Cisplatin on the early
apoptosis of these cells and showed that after 16 hours of 10 mg/
ml Cisplatin treatment, about 50% of HEK-499 cells remained
viable compared to 2.5% of control cells (Figure 6D).
We next examined the effect of RKIP expression on drug-
induced apoptosis in colon cancer cell lines. We treated HT29 and
HCT116 with the chemotherapeutic drug Doxorubicin (Adria-
mycin). Doxorubicin is a DNA-interacting drug that is widely used
in the treatment of a wide range of cancers. Mechanistically,
Doxorubicin inhibits topoisomerase-II, thereby introducing single-
and double-strand breaks into the DNA molecule and induces
apoptosis in cancer cells. The human colon carcinoma cell lines
HT29 and HCT116 underwent extensive apoptosis when treated
with doxorubicin (Fig. 7A). Apoptosis was measured by the
cleavage of caspase-8, caspase-9 and PARP, a downstream
physiological target of the caspase cleavage cascade (Fig. 7A).
We also measured the drugs induced cell death by trypan blue
staining and the results were consistent with the caspase and PARP
cleavage studies (data not shown). Similar to the data obtained
from the HEK-499 cell line, we observed a direct correlation
between the extent of apoptosis and the expression levels of RKIP
in HT29 cells (Figure 7A). In contrast, RKIP expression
modulation had no effect on apoptosis as measured by caspases
and PARP cleavage in HCT116 cells (Figure 7B). Similar results
were observed when apoptosis were measured by trypan blue
staining (not shown). To ensure the effect of RKIP is not drug
specific, we also examined the effect of RKIP expression on 5-FU
Figure 1. RKIP level modulation influences KEAP 1 protein expression and degradation. A, Western blotting (lower panel) and b-actin
normalized densitometric measurements (upper panel) for KEAP 1 in HEK-499 and control cells. B, Western blotting and b-actin normalized
densitometric measurement (bar charts) for KEAP 1 in RKIP induced cells (Doxy+/RKIP++ are Flp-In T-Rex 293 cells stimulated with Doxycycline and
Doxy2/RKIP+ are not treated/stimulated). C, Western blot and densitometric measurements of KEAP 1 protein in HT29 CRC cells transfected with
empty vector (EVC) or pBP vector that overexpresses flagged RKIP (fRKIP). D, Quantitative RT-PCR of normalized KEAP 1 mRNA fold changes in HEK-
293 control and HEK-499 RKIP depleted cells. E, GAPDH (left) b-actin (right) normalized KEAP 1 fold changes in mRNA expression in HT29 control
(KEAP1-1 pBP) and flagged RKIP (KEAP 1-1 RKIP) transfected cells. F, HEK-293 control and HEK-499 RKIP depleted cells exposed to cycloheximide (CHX;
35 mM) for the indicated times. KEAP 1 and GAPDH protein levels were analyzed by Western blotting. G, Western blotting for RKIP, KEAP 1 and tubulin
in HT29 CRC cells transfected with empty vector (EVC) or pBP vector that overexpresses flagged RKIP (fRKIP) exposed to cycloheximide (CHX; 35 mM)
for the indicated times. All western experiments were performed at least in duplicates and repeated twice. Asterisks indicate statistical significance
(p,0.05 compared to equivalent controls).
doi:10.1371/journal.pone.0029532.g001
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used in treatment of colon cancer. Unlike doxorubicin, 5-FU
induces apoptosis in cancer cells by a different mechanism. 5-FU is
a pyrimidine analog and functions as an inhibitor of thymidylate
synthase, which is an important enzyme in DNA replication. As
previously reported treatment of HCT116 with 5-FU for 48 h
induced extensive apoptosis (cell death) as measured by binding to
7 Amino-Actinomycin D (7-AAD) and annexin V (Figure 7C).
Similar to what was observed with doxorubicin, expression of
RKIP had no effect on apoptosis induced by 5-FU. Our Data
indicate that the effect of RKIP on apoptosis and chemoresistance
is cell specific in that cells like HCT116, which harbor activated
Ki-Ras, may not be influenced by molecules, like RKIP, that
inhibit the MAPK-pathway. Indeed, resistance to Cetuximab, an
Figure 2. Antioxidant treatments rescue KEAP 1 in RKIP –depleted HEK-499 cells. A, Upper panels show confocal images of HEK-293 and
499 stained with dihydro-ethidium bromide (DHE) as an indicator of ROS before and after treatments with 5 mM N-Acetylcysteine (N-Ac). The lower
bar chart represents the quantification of cell-number-normalized DHE intensities in depicted cells. B, Upper panel represents western blotting for
KEAP 1 and b-actin loading control in HEK-499 cells before and after treatment of cells with the antioxidants N-Ac and/or ALA. The lower western
panel depicts KEAP1 and RKIP protein levels in HEK-499 and HEK-293 after the indicated treatment. C, Densitometric measurements of b-actin
normalized KEAP 1 expression in an additional independent experiment after treatment of cells with 5 mM of n-Ac for 16 hours, showing the rescue
of KEAP 1 protein and concomitant reduction of total NRF2 in the treated HEK-499 cells. Western experiments were performed at least in duplicates
and repeated twice. Asterisks indicate statistical significance (p,0.05 compared to equivalent controls).
doi:10.1371/journal.pone.0029532.g002
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Ki-Ras driven CRC [45].
A proposed model summarizing the consequences of RKIP loss
or reduction and its association with therapeutic resistance is
shown in Figure 8.
Overall, our data have important ramifications for the
treatment of cancers characterized by RKIP reduction or loss in
that pharmacological or other interventions, which augment the
KEAP 1 related pathways or directly target NRF2 may be of
potential value in future personalized therapy.
Materials and Methods
Ethics Statement
The project number 2006-1302-07 has been ethically reviewed
by the Ethical committee of the Faculty of Medicine and approved
on 13
th April 2008. The immunohistochemistry procedure used on
human colorectal cancer tissues was in accordance with the ethical
standards implemented at University of Kuwait. We have not used
any de novo cell lines. All cell lines used were described previously
or referenced. No human subjects or vertebrates were used in this
study.
Cell culture and treatments
The generation of RKIP silenced and inducible cells, plasmid
designs, transfection, and selection protocols have been described
previously [33]. Flp-In T-Rex-293 cells were originally purchased
from Invitrogen (Paisley, UK) and authenticated by them (http://
tools.invitrogen.com/Content/SFS/ProductNotes/F_051025_Flp-In
-TS-TL-MKT-HL.pdf).HEK-293celllineswereoriginally purchased
from CRUK and were authenticated by the European Collection of
Cell Cultures (ECACC) in September 2009 using microsatellite
genotyping (PCR-based). The parental cell line for the HEK-499
derived cells is the aforementioned HEK-293 cell line. All cells were
used for experiments for 6–8 weeks before they were replaced with
fresh stocks, which are stored in liquid nitrogen. HEK 293 (Human
Figure 3. Immunohistochemical correlation between the expression of KEAP 1 and RKIP proteins in colorectal cancer tissues.
Magnification is at 406.
doi:10.1371/journal.pone.0029532.g003
Table 1. Correlation between RKIP and KEAP 1 protein expression in 105 colorectal cancer tissues by immunohistochemistry.
RKIP n (%)
Negative 14(13) Weak positive 34(32) Positive 57(55)
KEAP 1 n (%)
Negative 22 (21) 6 (5.7%)
* 10 (9.5%) 6 (5.7%)
Weak Positive 23 (22) 5 (4.8%) 10 (9.5%) 8 (7.6%)
Positive 60 (57) 3 (2.8%) 14 (13%) 43 (41%)*
n=number of patients.
*Significant at p=0.001 using two-sided Fisher’s exact test.
doi:10.1371/journal.pone.0029532.t001
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29532Figure 4. RKIP silencing induces nuclear translocation of NRF2. A, Shows western blotting and densitometric measurements (upper panel)
for NRF2, RKIP and b-actin loading control from total protein extracts of depicted cells. B, Shows western blots on nuclear fractions of HEK-control and
HEK-499 cells in duplicates with Aurora B as loading control. C, Immunofluorescent confocal microscopy for NRF2 in the depicted cells showing
increased nuclear localization of NRF2 in RKIP depleted HEK-499 cells. Western experiments were performed in duplicates and repeated twice.
doi:10.1371/journal.pone.0029532.g004
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Invitrogen, Grand Island, NY, U.S.A) supplemented with 10% FBS
(Gibco, Invitrogen, Grand Island, NY, U.S.A). The HEK-499 cells
containing the miRNA vector pcDNA
TM6.2-GW/EmGFPmiR-
PBP_miR_499 were cultured in 16DMEM media supplemented
with 5 mg/ml Blasticidin S HCL (Sigma, Carlsbad, CA, USA) and
incubated at 37uC, with 5% CO2. The Flp-In T-Rex-293 cell line
(Gibco, Invitrogen, Grand Island, NY, U.S.A) transfected with 1 mg
pcDNA5/FRT-FLAG-RKIP and 9 mg pOG44 (Invitrogen, V6005-
20) were cultured in 16DMEM (GIBCOH, Invitrogen Grand Island,
NY, USA), supplemented with 10% Tet-free approved FBS
(Clontech, Mountain View, CA, U.S.A). Switching on RKIP
expression was achieved with 100 ng/ml doxycycline (Sigma,
Carlsbad, CA, USA) for 48 hours prior to initiating the experiments.
The human colorectal cell lines HT29 was obtained from the
ATCC and cultured in McCoy’s 5A media supplemented with
10% FBS. The RKIP cDNA or empty vector control was
introduced into HT29 by retrovirus transduction as previously
described [12]. To determine the half-life of KEAP 1 protein,
HEK-293, HEK-499 and HT29 cells were treated with 35 mM
Cycloheximide, a de novo protein synthesis inhibitor for 10–
12 hours.
Immunohistochemistry
Sections from formalin-fixed paraffin-embedded colon cancer
were cut into 4 mm thick sections, deparaffinized in three changes
of xylene, and rehydrated through descending graded alcohols to
water. Antigen retrieval was achieved by automated pressure
Table 2. Genes involved in cellular protection found upregulated at mRNA level in HEK-499 RKIP depleted cells.
Cellular Function Gene name (Gene symbol)
Expression
fold-increase P value
*
Antioxidant proteins Glutamate-cysteine ligase, modifier (GCLM) subunit 3.15 0.009
Glutathione peroxidase 3 (GPX3) 3.03 0.028
Glutathione reductase (GSR) 2.63 0.0026
Glutathione synthetass (GSS) 3.35 0.0046
NAD(P)H dehydrogenase, quinone 1 (NQO1) 2.7 0.01
NAD(P)H dehydrogenase, quinone 2 (NQO2) 4.1 0.005
Thioredoxin (TXN) 2.2 0.003
Thioredoxin reductase 3 (TXNRD3) 2.5 0.0002
NADPH regeneration enzyme Malic enzyme 1 6.3 0.001
Phase I drug oxidation,
reduction and hydrolysis
Aldo-keto reductase (AKR) 1B 2.3 0.02
Aldo-keto reductase (AKR) 7A3 2.25 0.001
Aldo-keto reductase (AKR) 7A2 4.63 0.0003
Carbonyl reductase 1 (CR1) 3.4 0.025
Epoxide hydrolase 2 cytoplasmic (EPHX2) 2 0.001
Phase II drug conjugation Glutathione S-transferase A4 (GSTA4) 2.8 0.0003
Glutathione S-transferase (GSTP1) class pi 2.86 0.005
Glutathione S-transferase omega 1 3.65 0.001
Glutathione transferase zeta 1 (GSTZ1, maleylacetoacetate isomerase) 2.7 0.001
Glutathione S-transferase M3 (GSTM3 brain
{) 3.1 0.0006
Microsomal glutathione S-transferase (MGST) 1 6.8 0.009
Microsomal glutathione S-transferase (MGST) 2 2.24 0.002
Microsomal glutathione S-transferase (MGST) 3 2.3 0.001
Transport Multi-drug resistance-associated protein (Mrp4) ABCC4 3.8 0.01
Multi-drug resistance-associated protein (Mrp6) ABCC6 4 0.02
Solute carrier family 1(SLC1A5, Neutral amino acid transporter) 2.1 0.013
Solute carrier family 2 2.2 0.03
Solute carrier family 6 2.9 0.0003
Solute carrier family 39 2.1 0.0003
Chaperones Hsp40 (DnaJ) 3.4 0.00002
Growth factors Fibroblast growth factor 13 (FGF 13) 4.44 0.0001
peroxiredoxin family 1–5 (PRDX) 3.6 0.001
Transforming growth factor b receptor (TGFBR3) 3.01 0.01
Transcription factors v-maf musculoaponeurotic fibrosarcoma oncogene homolog avian (MAF) 3.4 0.03
Peroxisome proliferator activated receptor delta (PPARD) 2.8 0.013
*ANOVA statistics was used to compare probe intensity means between test and control samples.
doi:10.1371/journal.pone.0029532.t002
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29532Figure 5. RKIP modulates NRF2-ARE containing genes. A, mRNA expression levels by RT-PCR of RKIP and 8 NRF2-inducible genes showing
overexpression of genes involved in cellular protection from oxidative stress and chemotherapy in HEK-499 cells with silenced RKIP normalized to
HEK-293 control cells. B, Shows fold changes in mRNA expression of the NQO1 gene in HEK-499 cells normalized to their equivalent control. C, mRNA
expression levels of RKIP and the same 8 NRF2-inducible genes in Doxycycline induced Flip-in T-Rex 293 cells normalized to uninduced control cells.
D, mRNA expression fold change of NQ1 gene in Doxycycline treated Flip-in T-Rex 293 cells normalized to untreated control cells. The gene names
are shown on the X-axis. The fold change was calculated using DDCT normalized threshold method. Error bars represent 6S.D. Dashed lines
represent 1-fold change in expression. C, Repeat western blot and densitometric analysis of RKIP protein expression levels in the depicted cells
confirming the RKIP-mRNA data shown in panel A. Asterisks indicate statistical significance (p,0.05 compared to equivalent controls).
doi:10.1371/journal.pone.0029532.g005
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29532cooker in 10 mmol/L of sodium citrate buffer at pH 6. Slides were
then rinsed in running water for 5 minutes. Endogenous
peroxidase was blocked with 3% hydrogen peroxide in water for
15 minutes at room temperature. The slides were then rinsed in
water and immersed in PBS for 15 minutes at room temperature
followed by blocking in PBS with 5% goat serum (Vector
Laboratories, Inc., CA, U.S.A) for 1 hour. Sections were then
incubated with rabbit polyclonal antibody against RKIP protein
(dilution 1:900), or rabbit monoclonal antibody against KEAP 1
(dilution 1:100; Cell Signaling, Danvers, MA) diluted with
Antibody Diluent (S 0809; DAKOCytomation Norden A/S,
Glostrup, Denmark) and incubated overnight in a humidified
chamber at 4uC. After washing 3-times with PBS, the slides were
incubated with biotinylated secondary antibody at a dilution of
1:500 for 30 minutes (Biotinylated Anti-Rabbit IgG, Vector
Laboratories, Inc., CA, U.S.A). To detect the stain, VECTAS-
TAIN Elite ABC system (Vector Laboratories, Inc., CA, U.S.A)
was used following the manufacturer’s instructions. Slides were
imaged and quantified using an area and intensity scores described
previously [46].
Western Blotting
Cells at 70% confluency were lysed for 5 minutes on ice in lysis
buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1%Triton-X100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3V04, and
1 mg/ml leupeptin). Total cell lysates or nuclear fractions
(prepared by using NE-PER extraction kit from Thermo Scientific,
(Rockford IL, U.S.A) using the manufacturer’s protocol) were
sonicated briefly and centrifuged for 10 minutes at 14,0006ga t
4uC. An aliquot was removed to determine the protein
concentration (Thermo Scientific, Rockford, IL, U.S.A, BCA
protein Assay kit Reducing Agent Compatible). Equal amount of
protein extracts were separated by sodium dodecylsulphate–
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene fluoride (PVDF) membranes in transfer buffer
(25 mM Tris-HCl, 150 mM glycine, 20% v/v methanol and 0.1%
w/v SDS, pH 8.3) at 100 V at 4uC. Membranes were blocked for
1 hour at room temperature with 10% non-fat dry milk in Tris
buffered saline-Tween (TBST) solution (20 mM TrisHCl pH 7.6,
137 mM NaCl, 0.1% v/v Tween-20). Membranes were incubated
overnight at 4uC with 10 ml of rabbit polyclonal KEAP 1 or
NRF2 or RKIP antibodies (Santa Cruz Biotechnology, CA,
U.S.A) diluted in TBST with 5% w/v non-fat dry milk. After 3
washes with TBST membranes were incubated with horse radish
peroxidase coupled goat anti-rabbit secondary antibody diluted
1:10,000 in TBST for 2 hours at room temperature, and washed
with TBST. Detection was by chemiluminescence using a
commercial kit (Super Signal West Pico chemiluminescent
Substrate, Pierce). Membranes were stripped and rehybridized
with b-actin (Imigenex, CA, U.S.A) or Aurora B for nuclear
extracts (BD transduction, MD, U.S.A) to account for equal
Figure 6. RKIP depletion induces hydrogen peroxide and chemotherapeutic resistance. A, WST assay showing enhanced survival of RKIP
depleted HEK-499 compared to control cells with increasing hydrogen peroxide concentration. B, MTT assay/dose response curve depicting the
chemosensitivity of HEK-293 and HEK-499 after treatment with various Cisplatin concentrations for 16 hours and (C) for 60 hours. D, Early apoptosis
estimation using Anexin V of HEK-293 and 499 cells after treatment with 10 mg/ml Cisplatin for 16 hours demonstrating significant resistance of HEK-
499 cells to apoptotic death. Asterisks indicate statistical significance (p,0.05 compared to equivalent controls).
doi:10.1371/journal.pone.0029532.g006
Figure 7. RKIP level modulations alters HT29 but not HCT116 CRC cells’ sensitivity to chemotherapeutic agents. A, HT29 and B,
HCT116 cells were stably transfected with different retroviral expression vectors as indicated. Transfected cells were treated with doxorubicin for 48 h
before harvesting. Extracts were prepared for western immunoblot analysis with the specific indicated antibodies. C, HCTT116 cells were stably
transfected with different retroviral expression vectors as indicated. Transfected cells were treated with 5-FU for 48 h. Extracts were prepared for
cytometric analysis to examine binding to 7-ADD and annexin V.
doi:10.1371/journal.pone.0029532.g007
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Quantity one software of the GS-800 calibrated densitometer (Bio-
Rad, CA, U.S.A).
Confocal microscopy
5610
4 of Cells were grown at 37uC in a humidified CO2
incubator until 70% confluency was reached. 1–2 ml of cell
suspension were washed twice in phosphate PBS at room
temperature, then fixed with 4% paraformaldehyde in PBS
(pH 7.4) for 15 minutes at room temperature. After 3 washes
with PBS, cells were permeabilized by incubation in PBS
containing 0.1% Triton X-100 for 15 minutes at room temper-
ature, followed by 3 washes in PBS. Cells were then blocked by
incubation in PBS containing 1% bovine serum albumin (BSA)
(Sigma, St. Louis, MO, U.S.A) for 1 hour at room temperature.
The primary rabbit polyclonal antibody for NRF2 (Santa Cruz,
CA, U.S.A) was diluted 1:100 in PBS with 1% BSA (Sigma, St.
Louis, MO, U.S.A) and incubated at 4uC overnight. After 3
washes in PBS for 5 minutes each, anti-rabbit specific fluorophore-
conjugated secondary antibodies (1:500 dilution) was added for
1 hour at room temperature. Coverslips were then washed 3 times
in PBS for 5 minutes each, and visualized by LSM 510 META
confocal microscope (Carl Zeiss, Germany).
RT-PCR
Taqman real-time PCR Assay on Demand pre-designed plates
with accession numbers given in Figure 1 (Life Technologies,
Carlsbad, CA, U.S.A) were used to study NRF2 responsive genes.
Eachtranscriptwasassayedintriplicateandnormalizedto,GAPDH
(HS-99999905_ml) or 18S (HS-99999901_S1) housekeeping genes
using the equivalent control cells as calibrators. cDNA synthesis was
performed using High-Capacity cDNA Reverse Transcription Kit
(Life Technologies, Carlsbad, CA, U.S.A) following the manufac-
turer’s protocol. The reverse transcription conditions were: Step1–
25uC for 5 minutes, step2–37uC for 120 minutes and step3–85uC
for 5 minutes. PCR assays were performed using Taqman Gene
ExpressionMasterMix (Life Technologies,Carlsbad,CA,U.S.A)on
7500 ABI using the following conditions; 1 cycle of 95uCf o r
10 minutes, followed by 40 cycles at 95uC for 15 seconds then 60uC
for 1 minute. For relative quantification, the comparative CT
method, given by the formula 2
2DDCT, was utilized with the amount
of target, normalized to at least two separate endogenous references
and relative to a calibrator [33].
Cellular proliferation and death assays
The effects of Cisplatin on cellular proliferation were deter-
mined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) uptake method. For H2O2 effects on cells, H2O2
ranging from 0–200 mM was added to cells growing in complete
Media. Cell proliferation assay was performed using the
spectrophotometric cell proliferation reagent WST-1 following
the manufacturer’s protocol (Roche, IN, U.S.A). Early indicator of
apoptosis after 16 hours treatment of Cisplatin at 10 mg/ml was
detected by flowcytometry using the Annexin V- FITC/7AAD kit
(Beckman Coulter, CA, U.S.A) following the manufacturer’s
instructions. The cell preparations were analysed immediately
aided by the FC 500 flowcytometer (Beckman Coulter, CA,
U.S.A).
Statistics
SPSS software version 17 was used for statistical calculations.
Data are expressed as mean 6 S.D. Contingency table statistical
associations were calculated using two-sided Chi-square or Fisher’s
exact tests. Two-sampled Student’s t-test assuming unequal
variances was used to compare mean-data between two groups.
ANOVA statistics was used to compare means of 3 groups or
more. A level of p#0.05 was considered to be significant.
Supporting Information
Figure S1 Western blotting for KEAP 1 and GAPDH in HEK-
499 (left) and HEK-293 (right) from cells exposed to cycloheximide
(CHX; 35 mM) for the indicated times.
(TIF)
Figure S2 WST assay showing reduced survival after RKIP
induction by 100 ng/ml doxycycline treatment in Flp-In T-Rex-
293 cells. Increasing Doxycycline concentration did not influence
RKIP induction or cellular death. Asterisks indicate statistical
significance (p,0.05 compared to untreated cells).
(TIF)
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Figure 8. A proposed model for RKIP-induced drug resistance.
In unstressed normal cells and in the presence of abundant RKIP, NRF2
is kept in the cytoplasm by KEAP 1 binding and shuttled outside of the
nucleus by GSK3b, phosphorylated FYN protein. Upon loss or the
reduction of RKIP in a cell [19], inactivation/ubiquitination of KEAP1
ensues. In addition, RKIP loss/depletion causes the inactivation of
GSK3b through phosphorylation at its T390 residue by p38 [19]. Both
events, ? which may be partly oxidative stress driven, culminate in the
stabilization of NRF2 [30,31,32]. This consequently, enhances the
transcription of antioxidants and phase II detoxification genes
containing ARE-cis acting element culminating in the induction of
drug resistance.
doi:10.1371/journal.pone.0029532.g008
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